DK3380101T3 - Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil - Google Patents

Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil Download PDF

Info

Publication number
DK3380101T3
DK3380101T3 DK16869174.9T DK16869174T DK3380101T3 DK 3380101 T3 DK3380101 T3 DK 3380101T3 DK 16869174 T DK16869174 T DK 16869174T DK 3380101 T3 DK3380101 T3 DK 3380101T3
Authority
DK
Denmark
Prior art keywords
eif4
relationships
inhibiting
related procedures
procedures
Prior art date
Application number
DK16869174.9T
Other languages
English (en)
Inventor
Justin T Ernst
Siegfried H Reich
Paul A Sprengeler
Chinh Tran
Garrick Kenneth PACKARD
Alan Xin Xiang
Christian Nilewski
Theodore Michels
Original Assignee
Effector Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Effector Therapeutics Inc filed Critical Effector Therapeutics Inc
Application granted granted Critical
Publication of DK3380101T3 publication Critical patent/DK3380101T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK16869174.9T 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil DK3380101T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259828P 2015-11-25 2015-11-25
US201662334149P 2016-05-10 2016-05-10
PCT/US2016/063353 WO2017091585A1 (en) 2015-11-25 2016-11-22 Eif4-a-inhibiting compounds and methods related thereto

Publications (1)

Publication Number Publication Date
DK3380101T3 true DK3380101T3 (da) 2021-04-26

Family

ID=58720397

Family Applications (2)

Application Number Title Priority Date Filing Date
DK21153153.8T DK3888658T3 (da) 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK16869174.9T DK3380101T3 (da) 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK21153153.8T DK3888658T3 (da) 2015-11-25 2016-11-22 Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil

Country Status (21)

Country Link
US (5) US9957277B2 (da)
EP (2) EP3888658B1 (da)
JP (1) JP7105691B2 (da)
KR (1) KR102934754B1 (da)
CN (1) CN108601788B (da)
AU (1) AU2016359617B2 (da)
CL (1) CL2018001411A1 (da)
CO (1) CO2018006475A2 (da)
DK (2) DK3888658T3 (da)
EA (1) EA037370B1 (da)
ES (2) ES2870037T3 (da)
FI (1) FI3888658T3 (da)
IL (1) IL259433B (da)
MX (1) MX383051B (da)
MY (1) MY196749A (da)
PE (1) PE20181303A1 (da)
PH (1) PH12018501073A1 (da)
SG (2) SG11201804132UA (da)
TW (1) TWI731899B (da)
WO (1) WO2017091585A1 (da)
ZA (1) ZA201804070B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN107708702A (zh) 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩并三唑并二氮杂环庚三烯及其用途
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
EP3380479B1 (en) 2015-11-25 2022-12-07 Gilead Apollo, LLC Triazole acc inhibitors and uses thereof
CA3004796C (en) 2015-11-25 2023-11-14 Gilead Apollo, Llc Pyrazole acc inhibitors and uses thereof
BR112018009212B1 (pt) 2015-11-25 2022-06-14 Gilead Apollo, Llc Método para controlar patógenos fúngicos agrícolas
HUE053175T2 (hu) 2015-11-25 2021-06-28 Gilead Apollo Llc ACC-gátló észterek és azok alkalmazása
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
EP3619209A1 (en) * 2017-05-04 2020-03-11 Glenmark Pharmaceuticals S.A. Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
BR112019024719A2 (pt) * 2017-05-24 2020-06-16 Effector Therapeutics, Inc. Composições e métodos para resposta imunológica antitumor aprimorada
EP3755693B1 (en) * 2018-02-19 2024-06-12 Memorial Sloan-Kettering Cancer Center Agents and methods for treating dysproliferative diseases
KR102821508B1 (ko) 2018-04-10 2025-06-16 셀렉타 바이오사이언시스, 인코퍼레이티드 인지질-플라베글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법
CN109503418B (zh) * 2018-12-11 2021-06-08 河北合佳医药科技集团股份有限公司 一种甲基肼的制备工艺
WO2020172086A1 (en) * 2019-02-18 2020-08-27 The University Of Toledo Targeting lasp1, eif4a1, eif4b, and cxc4 with modulators and combinations thereof for cancer therapy
CN109971762B (zh) * 2019-04-24 2022-12-20 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 日本血吸虫eIF4A基因的siRNA及其应用
CA3154192A1 (en) 2019-10-10 2021-04-15 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
CN115996716A (zh) * 2020-03-24 2023-04-21 效应治疗股份有限公司 Eif4a抑制剂组合
WO2022089514A1 (zh) * 2020-10-28 2022-05-05 上海翰森生物医药科技有限公司 多环类生物调节剂、其制备方法和应用
CN112574078B (zh) * 2020-12-14 2022-09-13 湖南工程学院 2-砜基-2，3-二氢-1-茚酮及其衍生物及合成方法
CA3230542A1 (en) * 2021-09-01 2023-03-09 Krishnaraj Rajalingam Novel ras inhibitors
WO2023030687A1 (en) 2021-09-01 2023-03-09 KHR Biotec GmbH Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
CN115448860B (zh) * 2022-09-16 2024-04-02 上海海客宜家生物科技有限公司 一种邻甲硫基苯甲腈的合成方法
JP2026508161A (ja) 2023-02-23 2026-03-10 エスジェーピー バイオテック ゲーエムベーハー 新規ＲＡＳ阻害剤３ａＨ－シクロペンタ［ｂ］ベンゾフラン－３ａ－イル
WO2024175662A1 (en) 2023-02-23 2024-08-29 KHR Biotec GmbH Flavagline derivatives as ras inhibitors
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
CN121712777A (zh) * 2023-08-18 2026-03-20 皇家学术促进机构麦吉尔大学 Rna解旋酶抑制剂
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025092976A1 (zh) * 2023-11-03 2025-05-08 映恩生物制药（苏州）有限公司 蛋白翻译抑制剂
CN117700387A (zh) * 2023-11-30 2024-03-15 深圳湾实验室 类洛克米兰醇化合物、中间体及制备方法和应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
DE10356218A1 (de) 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
US7816544B2 (en) 2004-03-23 2010-10-19 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
EP1693059A1 (en) 2005-02-22 2006-08-23 Deutsches Krebsforschungszentrum Use of rocaglamide derivatives as NF-AT-specific inhibitors for the treatment of certain inflammatory diseases
CN100418532C (zh) 2005-06-17 2008-09-17 吕志民 治疗多种疾病的NF-κB化合物抑制剂
CA2652873A1 (en) 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
EP2457907A1 (en) 2010-11-16 2012-05-30 Université de Strasbourg Flavagline derivatives as neuroprotective agents
EA201390876A1 (ru) * 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) * 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
EP3021842A1 (en) 2013-07-17 2016-05-25 Deutsches Krebsforschungszentrum Sensitization of cancer cells to apoptosis induction by flavaglines and 5-hydroxy-flavones
WO2015075165A1 (en) 2013-11-22 2015-05-28 Deutsches Krebsforschungszentrum Translation inhibitors in high-dose chemo- and/or high-dose radiotherapy
FR3023290B1 (fr) 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto

Also Published As

Publication number Publication date
EA201891229A1 (ru) 2018-12-28
IL259433A (en) 2018-07-31
CO2018006475A2 (es) 2018-07-10
US20230295179A1 (en) 2023-09-21
US20230071483A1 (en) 2023-03-09
CL2018001411A1 (es) 2018-11-30
MY196749A (en) 2023-05-03
TWI731899B (zh) 2021-07-01
US9957277B2 (en) 2018-05-01
IL259433B (en) 2021-05-31
BR112018010235A2 (pt) 2019-03-19
EP3380101A1 (en) 2018-10-03
NZ743453A (en) 2024-07-26
JP7105691B2 (ja) 2022-07-25
AU2016359617A1 (en) 2018-07-05
ES2974439T3 (es) 2024-06-27
CN108601788A (zh) 2018-09-28
AU2016359617B2 (en) 2022-04-14
CN108601788B (zh) 2021-10-22
KR102934754B1 (ko) 2026-03-04
ZA201804070B (en) 2021-10-27
CA3006041A1 (en) 2017-06-01
EP3380101A4 (en) 2019-05-22
US20170145026A1 (en) 2017-05-25
MX2018006443A (es) 2019-08-01
SG11201804132UA (en) 2018-06-28
US10577378B2 (en) 2020-03-03
US11440917B2 (en) 2022-09-13
ES2870037T3 (es) 2021-10-26
KR20180096644A (ko) 2018-08-29
EP3888658B1 (en) 2023-12-27
EP3888658A1 (en) 2021-10-06
PH12018501073A1 (en) 2019-01-21
US20180298017A1 (en) 2018-10-18
EA037370B1 (ru) 2021-03-19
PE20181303A1 (es) 2018-08-09
TW201731832A (zh) 2017-09-16
US20200339590A1 (en) 2020-10-29
FI3888658T3 (fi) 2024-03-22
JP2019500331A (ja) 2019-01-10
SG10202004793YA (en) 2020-06-29
WO2017091585A1 (en) 2017-06-01
MX383051B (es) 2025-03-13
DK3888658T3 (da) 2024-03-18
EP3380101B1 (en) 2021-01-27

Similar Documents

Publication Publication Date Title
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
IL280863A (en) Autotaxin inhibitors and uses thereof
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3368534T3 (da) Valbenazin-ditosylat og polymorfer deraf
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3200615T3 (da) Kaloriefrie sødestoffer og fremgangsmåder til syntetisering
DK3258951T3 (da) Anti-pvrig antistoffer og fremgangsmåder for anvendelse
DK3215147T3 (da) Neurodæmpende norketamin-forbindelser og fremgangsmåder
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3265947T3 (da) Fremgangsmåde og system til kryptering
DK3212189T3 (da) Substituerede chromaner og fremgangsmåde til anvendelse deraf
DK3521289T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3193611T3 (da) Mk2-inhibitorer og anvendelser deraf
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3103715T3 (da) Styreindretning og styringsfremgangsmåde dertil
DK3128005T3 (da) Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3256598T3 (da) Svampestammer og anvendelsesfremgangsmåder
DK3384079T3 (da) Fibrøs konstruktion og fremgangsmåder i forbindelse hermed
DK3265641T3 (da) Stigørenhed og fremgangsmåde
DK3346056T3 (da) Rengøringssystem og fremgangsmåde